Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $70,210.00 in Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 10,325 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $6.80, for a total value of $70,210.00. Following the transaction, the chief executive officer directly owned 629,985 shares in the company, valued at approximately $4,283,898. The trade was a 1.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kevin Lee also recently made the following trade(s):

• On Monday, January 5th, Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $6.46, for a total value of $70,988.94.

Bicycle Therapeutics Stock Performance

Shares of BCYC traded down $0.04 during mid-day trading on Tuesday, hitting $6.57. 259,093 shares of the company’s stock were exchanged, compared to its average volume of 215,285. The stock’s 50-day moving average is $6.97 and its 200-day moving average is $7.42. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.03 and a fifty-two week high of $15.47. The company has a market cap of $455.76 million, a price-to-earnings ratio of -1.81 and a beta of 1.52.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.24. The firm had revenue of $11.73 million for the quarter, compared to the consensus estimate of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. As a group, equities research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on BCYC. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial began coverage on Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 price objective for the company. Royal Bank Of Canada restated a “sector perform” rating and issued a $11.00 target price (down previously from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Citizens Jmp lifted their price target on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research note on Friday, October 31st. Finally, JMP Securities set a $12.00 price target on Bicycle Therapeutics in a research report on Friday, October 31st. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.73.

Institutional Trading of Bicycle Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCYC. Assetmark Inc. lifted its position in Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after acquiring an additional 1,552 shares during the period. Ausdal Financial Partners Inc. purchased a new stake in shares of Bicycle Therapeutics during the second quarter worth approximately $70,000. Sei Investments Co. purchased a new stake in shares of Bicycle Therapeutics during the second quarter worth approximately $74,000. Virtus Investment Advisers LLC lifted its holdings in shares of Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after purchasing an additional 2,659 shares during the period. Finally, Ameriprise Financial Inc. purchased a new position in Bicycle Therapeutics in the 2nd quarter valued at $86,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.